Clinical Trials
17 trialsNCT02658968 2024-01-16
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
Phase 1 Completed
NCT02973113 2021-07-21
PREVALE
Baylor College of Medicine
Phase 1 Completed
NCT01447056 2020-02-07
MALTED
Baylor College of Medicine
Phase 1 Completed
NCT00058604 2020-01-18
EUCLID
Baylor College of Medicine
Phase 1 Completed
NCT01401530 2018-11-23
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 1 Completed
NCT02057445 2017-12-22
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
New York Medical College
Phase 1 Completed
NCT00028418 2015-03-25
Clofarabine in Chronic Lymphocytic Leukemia
FDA Office of Orphan Products Development
Phase 1 Completed
NCT00079716 2014-12-18
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
Seagen Inc.
Phase 1 Completed
NCT00103779 2014-12-18
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Seagen Inc.
Phase 1 Completed
NCT00655837 2014-12-18
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen Inc.
Phase 1 Completed
NCT00525447 2014-10-09
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Completed
NCT01273090 2014-01-30
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT00725634 2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00734890 2012-03-16
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01147991 2012-02-28
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Cancer Research UK
Phase 1 Completed
NCT00646139 2011-03-02
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Roswell Park Cancer Institute
Phase 1 Completed
NCT00002153 2005-06-24
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
NIH AIDS Clinical Trials Information Service
Phase 1 Completed